Abstract
Topotecan is a cytostatic drug whose antitumor activity is based on topoisomerase I inhibition. It is used in patients with metastatic ovarian cancer refractory to first-line or subsequent therapy.
Another indication is relapsed small-cell lung cancer (SCLC). Topotecan plus cisplatin is indicated for use in patients with cervical cancer.
The most common adverse effect is hematotoxicity, in particular neutropenia, thrombocytopenia and anemia. In the Czech Republic it is marketed as powder for infusion.